Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 1113 results for criteria

  1. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

  2. Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]

    Topic prioritisation

  3. Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]

    Topic prioritisation

  4. Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (TA883)

    Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.

  5. Varicose veins in the legs (QS67)

    This quality standard covers diagnosing and managing varicose veins in the legs of adults (aged 18 and over). It includes referral for specialist assessment and treatment options. It describes high-quality care in priority areas for improvement.

  6. Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.

  7. Rezafungin for untreated invasive candidiasis [TSID10768]

    Topic prioritisation

  8. IgPro20 for treating dermatomyositis [TSID12014]

    Topic prioritisation

  9. Falls: assessment and prevention in older people and in people 50 and over at higher risk (NG249)

    This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk and incidence of falls, and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.

  10. Teduglutide for treating short bowel syndrome in babies 4 to 12 months [TSID10755]

    Topic prioritisation

  11. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

  12. Risk assessment, referral criteria and shared care: What is the accuracy of the 4-variable Kidney Failure Risk Equation in children and young people living in the UK?

    Recommendation ID NG203/11 Question Risk assessment, referral criteria and shared care: What is the accuracy of the 4-variable Kidney...

  13. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

    This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).

  14. Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

    Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.